PURPOSE: To describe the anatomical and functional outcomes in @entity1 with exudative @entity1020 ( @entity1020 ) undergoing ranibizumab therapy in real-life practice. METHODS: This is a retrospective analysis of @entity1 with exudative @entity1020 treated with ranibizumab. Visual acuity (VA) and optic coherence tomography characteristics at baseline and at the end of the follow-up, clinical forms of the disease, delay between diagnosis and treatment as well as the number of follow-up visits and of intravitreal injections were collected. RESULTS: One hundred and seventy-nine @entity1 (220 eyes) were followed up during a mean of 24 months. The mean delay between diagnosis and treatment was 20.3 days (SD   16.8). VA stabilization was observed in 46.4% of eyes, 21.7% of eyes gained >= 15 ETDRS (Early Treatment @entity6 Study) letters and 31.9% lost >= 15 ETDRS letters. The mean central retinal thickness decreased from 380.6  m at baseline to 295.6   m at the final examination. A lower baseline VA score was associated with a greater gain of letters (OR 1.04, 95% CI 1.02-1.06; p < 0.001). CONCLUSION: Shortening the delays in diagnosis appears to be a key point in real-life situations.    2015 S. Karger AG, Basel.

Intravitreal Ranibizumab in Daily Clinical Practice for Age-Related XXXX : Treatment of Exudative Age-Related @entity1020 in Real Life.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['AMD', 'age-related macular degeneration'] @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetic Retinopathy']
@entity1020 :: (MESH:D008268,Disease) :: ['Macular Degeneration']
